BA3011-002

Research code: BA3011-002
Research name: hase II clinical trial of mecbotamab vedotin (BA3011) as monotherapy and in combination with nivolumab in the treatment of adult patients with metastatic non-small cell lung cancer who have previously progressed on treatment with PD-1/L1, EGFR or ALK inhibitors or who have intolerance to these inhibitors occurs.
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD